ACRV Projected Dividend Yield
Acrivon Therapeutics Inc ( NASDAQ : ACRV )Acrivon Therapeutics is a clinical stage biopharmaceutical company developing oncology medicines by utilizing its proprietary proteomics-based patient responder identification platform. Co.'s Clinical Candidate ACR-368 is a selective small molecule inhibitor targeting CHK1 and CHK2. Using its Acrivon Predictive Precision Proteomics (AP3) platform, Co. has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature that can predict patient response to ACR-368 monotherapy. Co. also has two preclinical drug programs designed to take advantage of its AP3 platform and the ability to predict tumor sensitivity based on custom OncoSignature tests. 20 YEAR PERFORMANCE RESULTS |
ACRV Dividend History Detail ACRV Dividend News ACRV Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |